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ABSTRACT
Objective: The use of retail purchasing data may
improve adherence prediction over approaches using
healthcare insurance claims alone.
Design: Retrospective.
Setting and participants: A cohort of patients who
received prescription medication benefits through CVS
Caremark, used a CVS Pharmacy ExtraCare Health Care
(ECHC) loyalty card, and initiated a statin medication in
2011.
Outcome: We evaluated associations between retail
purchasing patterns and optimal adherence to statins
in the 12 subsequent months.
Results: Among 11 010 statin initiators, 43% were
optimally adherent at 12 months of follow-up. Greater
numbers of store visits per month and dollar amount
per visit were positively associated with optimal
adherence, as was making a purchase on the same day
as filling a prescription (p<0.0001 for all). Models to
predict adherence using retail purchase variables had
low discriminative ability (C-statistic: 0.563), while
models with both clinical and retail purchase variables
achieved a C-statistic of 0.617.
Conclusions: While the use of retail purchases may
improve the discriminative ability of claims-based
approaches, these data alone appear inadequate for
adherence prediction, even with the addition of more
complex analytical approaches. Nevertheless,
associations between retail purchasing behaviours and
adherence could inform the development of quality
improvement interventions.
INTRODUCTION
Suboptimal adherence to evidence-based
medications for coronary artery disease and
other chronic conditions can lead to poten-
tially avoidable morbidity, mortality and
health spending.1 2 The accurate prediction
of who will ultimately become non-adherent
could help identify which patient groups
would most beneﬁt from interventions to
maintain adherence.3–5 Traditional approaches
to prediction generally use insurance reim-
bursement claims data from commercial or
government-sponsored insurance programmes
to generate clinical and demographic variables
measured at or prior to treatment initiation.
Other methods to identify non-adherence rely
on patient self-report, pill counts or electronic
pill monitors, but are not useful for identify-
ing non-adherence before it occurs.6 7 While
many of the variables available in insurance
databases are correlated with adherence, for
example, age and race, they provide weak
discrimination between adherers and non-
adherers.8–12
Good adherence has repeatedly been
linked to other healthy behaviours, such as
Strengths and limitations of this study
▪ Using a unique data set combining prescription
claims data with retail purchase data, this study
aims to improve adherence prediction accuracy
where traditional claims-based approaches have
typically performed poorly.
▪ This study uses both investigator-specified and
empirical predictor selection to evaluate and
maximise prediction accuracy.
▪ This study comprises complete dispensing infor-
mation for a patient and so minimal misclassifi-
cation of the outcome and other medication use
covariates is expected.
▪ Members with loyalty cards may not use them at
every purchase, and these data do not capture
retail purchases patients make at non-CVS
Pharmacy locations.
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greater use of preventive healthcare services, inﬂuenza
vaccination and compliance with recommended screen-
ing programmes through a phenomenon known as the
‘healthy user effect’.13–15 Thus, the use of richer data
sources that capture activities reﬂecting such healthy
attributes and behaviours might improve adherence pre-
diction over approaches using healthcare claims alone.
Such rich ‘big data’ sources have had success in predict-
ing similarly complex individual behaviours. For
example, mobile phone data have been used to describe
individual mobility patterns and infer friendship net-
works, while transactional data from credit and debit
cards have been used to predict consumption pat-
terns.16–20
The extent to which enrichment of insurance claims
data with in-pharmacy purchasing information may
improve the prediction of medication ﬁlling and reﬁll-
ing behaviours has not been evaluated until now. Using
a unique data set combining prescription claims data
with retail purchase data of individuals at CVS Pharmacy
locations, we explored the association between purchas-
ing behaviours in the year prior to initiation of a statin
medication and adherence in the subsequent year. Our
approach employed a combination of investigator-
speciﬁed purchasing predictors and those selected by a
high-dimensional propensity score (hd-PS) algo-
rithm.21 22 We additionally compared logistic regression
results to those enhanced with boosting techniques, a
machine-learning method that identiﬁes non-linear asso-
ciations between predictors and outcome or deep inter-
actions among predictors, which may be useful for
modelling behaviour as complex as medication adher-
ence.23 24 Enhanced predictive ability from this linked
data set could improve targeting of patients who stand
to beneﬁt from adherence-improving interventions,
while the co-occurrence of in-pharmacy purchasing and
ﬁlling behaviours could lead to the development of
novel interventions.
METHODS
Data source
We used a data set linking prescription claims and retail
purchase data for individuals receiving prescription
medication insurance beneﬁts through CVS Caremark, a
pharmacy beneﬁts manager that provides coverage to
more than 65 million members annually making pur-
chases at CVS Pharmacy stores using a CVS Pharmacy
‘ExtraCare Health Care’ (ECHC) loyalty card. Retail
purchasing data consisted of item-level data on each pur-
chase, including date of visit, dollar amount paid, quan-
tity, and whether the product was on sale or a CVS
brand item. Data also included information from CVS
Pharmacy’s internal product hierarchy, a system for
classifying products according to merchandise group
(eg, consumer health), category (eg, pain relievers) and
subcategory (naproxen). Prescription claims data
included information on all paid prescription claims
including the brand and generic drug name, dose, days
supply, patient paid amount and insurer paid amount
from all prescription claims, as well as patient gender,
age group and region of residence. Data on education
level, median income and racial distribution in a zip
code, derived from 2010 Census data by CVS Health,
were additionally provided.
All purchasing data were linked to prescription claims
data based on a unique masked patient identiﬁer. To
safeguard the anonymity of the participants included in
the analysis, the linked data set used by the research
team did not contain any direct patient identiﬁers. The
Institutional Review Board of Brigham and Women’s
Hospital approved this study.
Study population
The study population consisted of patients who received
prescription medication beneﬁts through CVS Caremark,
a pharmacy beneﬁts manager that serves over 65 million
individual members nationwide who also received a CVS
Pharmacy ECHC loyalty card from their health plan.
Whereas members are enrolled individually, loyalty cards
do not require identiﬁcation to be used and thus can be
shared, typically within a household.
From this cohort, we identiﬁed individuals newly initi-
ating a statin or statin combination drug between 1
January 2011 and 31 December 2011. A patient’s index
date was deﬁned as the date of the ﬁrst prescription
ﬁlled during the study window. Patients were required to
have continuous insurance enrolment for 180 days
before the index date and 1-year postindex (ﬁgure 1).
New use was deﬁned as not having any statin ﬁlled in
the 180 days prior to the index date. Finally, we
restricted our cohort to patients with at least three
Figure 1 Study design and data sources. ECHC, ExtraCare Health Care.
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unique store visits in which the ECHC card was used in
the year prior to the ﬁrst statin prescription to enrich
the data set from which purchasing predictors were
drawn.
Adherence measures
We measured medication adherence using prescription
ﬁll data from prescription claims. By stringing together
all paid ﬁlls, we created a statin ‘supply diary’ that indi-
cates whether on each day for the year after the index
date patients had a statin medication available to them.
From this diary, we calculated a proportion of days
covered (PDC), deﬁned as the number of days with
medication available divided by 365. We deﬁned ‘full
adherence’ as a PDC≥0.8, which corresponds to the
level of use above which patients with coronary artery
disease derive clinically relevant beneﬁt from statins25
and the threshold employed by most quality
measures.26 27
Adherence predictors
Investigator-speciﬁed clinical and demographic variables: We
deﬁned nine clinical characteristics based on prescrip-
tion claims incurred during the 180 days before the
index date (table 1). Clinical characteristics included
the number of unique medications taken and the pres-
ence of maintenance medications likely to inﬂuence
adherence to a cardiovascular medication, including
antihypertensive, antiplatelet, oral antidiabetic, chronic
obstructive pulmonary disease and asthma, heart failure,
antidepressant, antiarrhythmic, anticoagulant, and
osteoporosis medications. Characteristics of the index
prescription included whether or not it was a generic
(as compared with a branded medication) and the
dollar amount the patient must pay at the pharmacy
(copayment amount). Demographic information
included age group and sex. Information at the zip code
level included race, education and median household
income.
Investigator-speciﬁed purchasing variables: Using the retail
purchasing data, we deﬁned 12 variables that we
hypothesised would be associated with adherence. These
variables were developed based on a manual review by a
team of clinicians and epidemiologists of the purchasing
data for a random sample of 100 patients, 50 of whom
were fully adherent to their statin and 50 of whom were
not. Our team ﬁrst discussed candidate variables. We
subsequently reﬁned potential predictors while blinded
to the patients’ observed adherence and then using
patients’ observed adherence to calibrate how the vari-
ables were deﬁned. In all instances, we used descriptors
from the internal product hierarchy, consisting of mer-
chandise group, category and subcategory to assign indi-
vidual products. After the ﬁnal list of variables was
agreed on, they were generated for the entire cohort for
use as potential predictors.
The ﬁnal list of investigator-speciﬁed behaviours is pre-
sented in table 2. Behaviours 1, 2 and 3 were based on
products within a given purchasing category. For
example, we classiﬁed each product listed in the ‘food’
merchandise group as being ‘healthy’ or ‘unhealthy’
based on product descriptions, hypothesising that
unhealthy foods would be associated with worse adher-
ence. Similarly, we classiﬁed all products listed in the
‘consumer healthcare’ merchandise group as being for
preventive or symptomatic purposes, or both.
Behaviours 4 and 11 recorded the number of visits in
which any product in the ‘consumer healthcare’ mer-
chandise group was purchased. Behaviours 5–9 used
ﬁelds outside of the product hierarchy to describe the
amount of money spent, whether products were pur-
chased on sale, and the number of monthly store visits
with a purchase. Behaviour 10 used retail purchasing
Table 1 Cohort baseline characteristics
Demographics N (%)
Female sex 4345 (39.6%)
Age (mean) 59.3
Median household income in zip
<$50 000 3719 (33.8%)
$50 000–$99 999 6457 (58.6%)
$100 000+ 834 (7.6%)
Per cent black in zip, mean (SD) 12.3 (17.9%)
Per cent ≥HS education, mean (SD) 86.9 (8.5%)
Region
Midwest 2122 (19.3%)
Northeast 3053 (27.7%)
South 4750 (43.1%)
West 1085 (9.9%)
Index statin (generic)
Amlodipine/atorvastatin 56 (0.5%)
Atorvastatin 2474 (22.5%)
Fluvastatin 23 (0.2%)
Lovastatin 436 (4.0%)
Niacin/lovastatin 17 (0.2%)
Niacin/simvastatin 69 (0.6%)
Pitavastatin 96 (0.9%)
Pravastatin 1441 (13.1%)
Rosuvastatin 1760 (16.0%)
Simvastatin 4638 (42.1%)
Copayment index statin prescription,
mean (SD)
$24.70 ($26.10)
Comorbidity medications N (%)
Coronary artery disease 391 (3.6%)
Asthma/COPD 1172 (10.6%)
Diabetes 2219 (20.2%)
Congestive heart failure 246 (2.2%)
Hypertension 6105 (55.4%)
Mental health and depression 2074 (18.8%)
Platelet inhibitor 603 (5.5%)
Loop diuretic 545 (5.0%)
Antiarrhythmics 122 (1.1%)
Osteoporosis 481 (4.4%)
Anticoagulant 383 (3.5%)
Total number of medications, mean (SD) 5.3 (4.2)
COPD, chronic obstructive pulmonary disease; HS, higher
secondary.
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Table 2 Retail purchasing behaviour association with statin adherence
Median (IQR) and proportion above median
Association with optimal statin adherence 12 months after
initiation
#
Patient-level retail purchasing
behaviour
Full cohort
(N=11 010)
Optimally
adherent (N=4691)
(%)
Suboptimally
adherent
(N=6319) (%)
Univariable OR
(95% CI) p Value
Multivariable OR
(95% CI)* p Value
1 Per cent of visits with ≥1 unhealthy food
purchase
25 (35) 45.1 50.1 0.996 (0.994 to 0.997) <0.0001 0.998 (0.996, 1.001) 0.14
2 Per cent of visits with ≥1 preventive
consumer healthcare product purchased
18 (33) 50.9 48.0 1.005 (1.003 to 1.007) <0.0001 1.002 (0.999, 1.005) 0.11
3 Per cent of visits with ≥1 symptomatic
consumer healthcare product purchased
33 (31) 48.4 44.5 1.003 (1.001 to 1.004) 0.001 1.001 (0.997, 1.004) 0.73
4 Per cent of visits with ≥1 consumer
healthcare product purchased
44 (40) 50.9 46.9 1.003 (1.002 to 1.005) <0.0001 0.999 (0.995, 1.003) 0.63
5 Per cent of all purchased items that were
on sale
35 (25) 49.2 49.1 1.00 (0.998 to 1.002) 0.78 1.000 (0.998, 1.002) 0.92
6 Per cent of all purchased items that were
CVS brand
23 (20) 51.1 47.5 1.005 (1.003 to 1.007) <0.0001 1.003 (1.000, 1.006) 0.02
7 Maximum number of items in a visit 5 (4) 41.1 39.5 1.01 (0.999 to 1.02) 0.07 0.988 (0.973, 1.002) 0.09
8 Dollar amount spent per visit $15 ($11) 48.2 43.4 1.01 (1.007 to 1.014) <0.0001 1.012 (1.007, 1.016) <0.0001
9 Number of visits per month 0.9 (1.2) 32.5 27.9 1.07 (1.04 to 1.10) <0.0001 1.091 (1.004, 1.185) 0.04
10 Ratio of index statin copayment amount
vs median income in zip code of
residence
0.2 (0.5) 45.8 50.0 0.79 (0.73 to 0.85) <0.0001 0.795 (0.732, 0.863) <0.0001
11 Per cent of all consumer healthcare
product purchases that were on sale
N (%)
No consumer healthcare purchases
made
864 (7.8%) 7.0 8.5 REF REF
<25% consumer healthcare purchases
were on sale
9540 (86.6%) 87.0 86.4 1.22 (1.06 to 1.41) 0.68 0.995 (0.916, 1.082) 0.91
≥25% consumer healthcare purchases
were on sale
606 (5.5%) 6.0 5.1 1.42 (1.15 to 1.76) 0.01 1.016 (0.884, 1.167) 0.83
12 A prescription fill for any medication
occurred on the same day as the store
visit, yes vs no
7001 (63.6%) 65.4 62.3 1.14 (1.06 to 1.24) 0.001 1.132 (1.006, 1.274) 0.04
*Includes adjustment for age, sex, region, zip code-level race, household income, and education level, and interaction terms between behaviors #1 and #12 and behavior #9.
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data in conjunction with 2010 Census data derived from
patient zip code of residence, hypothesising that a
higher burden of drug costs relative to neighbourhood
income might inﬂuence adherence. Behaviour 12 add-
itionally used purchasing and prescription drug data in
the 180 days prior to statins initiation to observe whether
ﬁlling coincided with a retail purchase, hypothesising
that patients with co-ﬁlling would be more likely to be
adherent.
High-dimensional propensity score approach: To more com-
pletely use all of the available data for adherence predic-
tion without any a priori hypotheses, we applied a hd-PS
variable selection algorithm to the retail purchasing data
and prescription claims data incurred during the
180 days prior to statin initiation.21 22 When applied to
prescription claims, the hd-PS algorithm creates binary
variables that indicate the frequency of each unique
medication. When applied to purchasing data, the algo-
rithm indicates the frequency of each product subcat-
egory. The hd-PS algorithm can screen thousands of
variables for an empirical association with a study expos-
ure, and ranks variables with the expectation that a large
number of highly ranked variables can collectively proxy
for unmeasured confounders. Equivalently, since our
goal was prediction rather than confounder adjustment,
we used the hd-PS approach to identify a large collec-
tion of variables that could be proxies for underlying
behavioural constructs that may be predictive of adher-
ence as has been done previously.28 We ran hd-PS on
two sets of data: ﬁrst, using all prescription claims data
available and second, using all products in CVS
Pharmacy’s retail product hierarchy, in each case select-
ing the 200 variables with the strongest associations with
adherence.
Statistical analyses
We ﬁrst evaluated associations between the 12
investigator-speciﬁed purchasing variables and optimal
adherence during follow-up using logistic regression
models. We measured univariable associations as well as
a multivariable model adjusting for all purchasing vari-
ables, two prespeciﬁed interaction terms, and demo-
graphic covariates to observe the magnitude and
direction of each effect after accounting for other
characteristics.
To compare the discriminative ability of different
groups of adherence predictors, we estimated six
models. In models with hd-PS predictors, the models
included predictors selected by the algorithm as model
covariates. These models were evaluated with respect to
their ability to discriminate between patients who were
and were not adherent during the year after initiation,
as measured by the C-statistic. This measure ranges from
0.5 to 1.0, corresponding to a completely non-
informative model and perfect prediction, respectively.29
To avoid the ‘overoptimism’ bias associated with evaluat-
ing model prediction accuracy in the same data that
were used to estimate the model, we performed 10-fold
cross-validation.30 Each model was predicted using both
logistic regression and generalised boosting regression, a
non-parametric data-mining technique capable of ﬁtting
highly predictive models with deep interactions among
predictors.23 Logistic regression models were estimated
using SAS (SAS, V.9.3, Cary, North Carolina, USA); all
models were re-estimated using the generalised boosting
algorithm, as implemented in the R package gbm.11 To
identify the best-performing model(s), we compared the
cross-validated C-statistic across all logistic and boosted
regression models. Finally, we re-estimated our six
Figure 2 Consort diagram.
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prediction models with the addition of retail purchase
predictors from the ﬁrst 3 months after initiation to
observe whether changes in retail patterns during this
period might provide additional improvement in adher-
ence prediction.
RESULTS
Patient characteristics
The cohort consisted of 11 010 patients initiating a
statin during the study period and who used their loyalty
card on at least three visits prior to initiation (ﬁgure 2).
Included versus excluded patients were similar in age
and gender composition (59.3 vs 57.8 years, and 40.3%
vs 39.6% female), as well as regional distribution,
though included patients had a higher proportion of
patients from the Northeast (28% vs 18%). Patients
tended to be male (60.4%) with an average age of
59 years (table 1). Simvastatin (42.1%) and atorvastatin
(22.5%) were the most commonly used statins. More
than half of the patients (55.4%) were concomitantly
taking an antihypertensive while one-ﬁfth (20.2%) were
taking an oral antidiabetic at the time of statin initiation.
On average, patients ﬁlled prescriptions for more than
ﬁve unique medications in the year prior to index. At
12 months, 4691 (42.6%) of patients were optimally
adherent to their statin medication.
Purchasing patterns
Results from investigator-speciﬁed purchasing variables
are presented in table 2. The median number of
monthly visits was 0.9 (IQR 1.2). During these visits,
patients purchased a median of 5 (IQR 4) items, and
spent a median of $15 (IQR $11). These visits included
an unhealthy food product on average 28% of the time,
while on average nearly half (45%) included the pur-
chase of a consumer healthcare product. The median
patient purchased a symptomatic consumer healthcare
product on 33% of visits (IQR 31%), and a preventive
consumer healthcare product on 18% of visits (IQR
33%).
Nearly two-thirds (63.6%) of patients made a store
purchase on the same day as a prescription ﬁll in the
180 days prior to index. Of all the items purchased
during the study period, a median per cent of 35 (IQR
25) were on sale.
Relationship between potential predictors and adherence
In univariable analysis, greater numbers of visits per
month and dollar amount per visit were positively
associated with adherence, as was making a purchase on
the same day as ﬁlling a prescription and a higher pro-
portion of visits with preventive and symptomatic health-
care purchases. In contrast, unhealthy purchases and
higher copayment amounts relative to median income
in zip code of residence were associated with lower
adherence; the latter association was additionally
observed within strata of median income in zip code
(<$50 000; $50 000–$100 000; >$100 000). While the pro-
portion of visits with a CVS brand product was signiﬁ-
cantly associated with adherence, the per cent with an
item on sale was not (p<0.0001 vs p=0.78). Higher statin
copayments relative to median income in zip code of
residence were associated with worse adherence
(p<0.0001). Results from multivariable analyses adjusted
for demographic and all purchasing behaviour variables,
as well several multiplicative interaction terms, were
similar.
Prediction models
The results of prediction models are shown in table 3.
Both models using purchase variables, one with
investigator-speciﬁed variables and the other with vari-
ables selected by the hd-PS, had similar predictive ability
(C-statistic for both: 0.563). Investigator-speciﬁed clinical
variables achieved a C-statistics of 0.599, while models
with both clinical and retail purchase variables had
slightly greater discriminative ability (C-statistic: 0.617).
Generalised boosting regression improved prediction
slightly in ﬁve out of six models; the highest C-statistic
achieved was 0.621 in the model with clinical and retail
purchase variables. Results from logistic regression
models incorporating retail purchase data from the
3 months after initiation were similar (see online
supplementary appendix A).
Table 3 Model prediction
C-statistic
Adherence predictors
Logistic
regression
Boosted
regression
Investigator-specified retail
purchase variables
0.563 0.537
High-dimensional propensity
approach for retail purchase data
0.563 0.573
Investigator-specified clinical
variables
0.599 0.602
Investigator-specified clinical
variables
High-dimensional propensity
approach for retail purchase data
0.599 0.611
Investigator-specified clinical
variables
Investigator-specified retail
purchase variables
0.607 0.610
Investigator-specified retail
purchase variables
Investigator-specified clinical
variables
High-dimensional propensity
approach for retail purchase data
High-dimensional propensity
approach for prescription claims
data
0.617 0.621
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DISCUSSION
One of the central challenges in predicting adherence is
the multifaceted nature of adherence itself. Adherence
is the result of complex interactions between patients,
providers and the healthcare system, as well as of
behavioural characteristics unique to patients them-
selves.8 31–33 It is, therefore, not surprising that efforts to
predict adherence using insurance claims data have gen-
erally yielded disappointing results.12 28 34 Pharmacies
also have access to data about retail purchases for goods
such as snacks and beverages, beauty products, and
over-the-counter medicines that patients make at the
‘front of the store’. Accordingly, we hypothesised that
retail purchasing transactions, conﬁdentially linked to
prescription claims, could be a rich source of data to
capture adherence-related behaviours that are otherwise
not observable using routinely collected data. In a
cohort of more than 11 000 statin initiators, 43% of
whom were optimally adherent at 12 months, we found
that several variables generated with these data tend to
be associated with long-term medication use. In speciﬁc,
after multivariable adjustment for all other predictors,
more monthly visits, a great dollar amount spent per
visit, a greater proportion of items that were
store-branded, and making a purchase and ﬁlling a pre-
scription on the same visit were signiﬁcantly associated
with optimal adherence to statin medications in the year
after initiation. While small in magnitude, these associa-
tions nonetheless suggest that greater retail purchase
activity, in the form of store visits and amount of money
spent, correlates with adherence, as does the purchase
of lower priced equivalent store brand products, which
could be a manifestation of the well-documented
‘healthy user’ effect.
While the use of retail purchasing data may improve
the discriminative ability of traditional claims-based
approaches, these data alone appear inadequate for
adherence prediction, even with the addition of more
complex analytical approaches, including the use of a
hd-PS algorithm and boosting techniques. There are
several potential reasons for this apparent discrepancy.
Most obviously, retail transaction data may not actually
sufﬁciently capture true underlying constructs reﬂective
of medication adherence. Just as adherence behaviours
cannot be explained by health system use and disease
state information as captured in insurance claims data,
retail purchase data that tabulate the frequency, quantity
and types of purchases made may not encode patterns
or individual behaviours that accurately discriminate
adherers from non-adherers.28 Additionally, information
on personal behaviours such as diet and exercise, struc-
tural barriers such as language and health literacy, and
degree of social support, which was not available in our
analysis, may be critical to adherence prediction.
Several methodological features may have also
impeded our ability to predict adherence. By using pur-
chases made prior to statin initiation, we did not observe
how purchasing behaviours may change over time
following statin initiation, which in turn may help
predict a patient’s longitudinal adherence pattern. We
repeated our analyses including retail purchases made
in the ﬁrst 3 months after initiation as potential predic-
tors and found very similar model discriminative ability.
This suggests that postinitiation variables may not be
informative. Additionally, the structure of the data set
may have reduced our ability to model the strongest pre-
dictors of medication adherence. Investigator-speciﬁed
purchasing variables leveraged only a brief product
description available in the data, while the predictors
selected by the hd-PS algorithm had a median preva-
lence of only 1%. A richer data set with greater informa-
tion on product and pharmacy characteristics including
location, combined with an analytical approach that
includes time-varying prediction or network analysis,
may better capture and characterise hypothesised beha-
viours and thus achieve better adherence prediction.
Whereas some investigator-speciﬁed purchasing variables
may have had an overlap in the products classiﬁed (eg,
CVS branded products tend to be mostly healthcare-
related), this would not have affected our models’
discriminative ability.
Nevertheless, several of the observed associations
between retail purchasing behaviours and adherence
could be useful for the development of new quality
improvement interventions by pharmacies or payers. For
example, the association between greater frequency of
visits as well as retail purchasing on the same day as a
medication ﬁll and adherence may be markers of con-
venience of the pharmacy, an individual’s level of
comfort in the store, or an underlying routine that
adherent patients develop around pharmacy visits. In
this way, identifying patients with irregular store visits
and with store visits that do not coincide with a medica-
tion ﬁll may represent an opportunity to link medication
taking with other daily activities such as shopping.
Speciﬁc interventions could target patients taking medi-
cations for chronic disease who have a high frequency of
unhealthy food purchases for interventions tailored to
adherence and dietary modiﬁcation.
Several limitations to our study should be acknowl-
edged. Members with loyalty cards may not use them at
every purchase, and these data do not capture retail pur-
chases patients make at non-CVS Pharmacy locations.
Additionally, other family members may use an indivi-
dual’s loyalty card. The former would result in an under-
estimate of store visit frequency, the latter in an
overestimate, and both would result in misspeciﬁcation
of other variables in either direction, which, from a pre-
diction perspective, would reduce model discrimination.
Finally, behaviours of individuals who have obtained and
regularly use a loyalty card may not be generalisable to
all individuals using both the retail and pharmacy sec-
tions of the store, nor to patients who stopped being
covered by Caremark during follow-up.
In summary, we found several retail purchasing beha-
viours to be associated with adherence to statins in the
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year after initiation, some of which might be useful for
the development of new quality improvement interven-
tions by pharmacies or payers. In contrast, the use of
retail purchasing data similar to those to which we had
access appears not to meaningfully add to efforts to dis-
criminate adherers from non-adherers.
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